Joinn Laboratories(China)Co.,Ltd. (6127.HK)
HKSE · HKD · Healthcare · Diagnostics & Research
HK$22.50 (-2.68%) as of
Key statistics
- Market cap
- 16.86B
- P/E (TTM)
- 15.31
- Forward P/E
- 74.09
- EPS (TTM)
- 1.470
- Dividend yield
- 0.60%
- 52-week range
- 15.130 – 32.580
- Beta
- 0.87
- Revenue (TTM)
- 1.69B
- Profit margin
- 58.15%
- Analyst target
- HK$25.02
- Volume
- 2.79M
About Joinn Laboratories(China)Co.,Ltd.
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Beijing, China
- Employees
- 2,500
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.